Table 4.

Multivariable-adjusted HRs (95% CIs) for prostate cancer by time to diagnosis in relation to hematologic indices.

Diagnosed <4 years from baselineDiagnosed ≥4 years from baseline
CasesHR (95% CI)CasesHR (95% CI)Phet
Red blood cell
 Red blood cell count (1012 cells/L)2,9381.04 (1.01–1.08)2,7851.10 (1.06–1.14)0.07
 Red blood cell distribution width (%)2,9381.02 (0.98–1.06)2,7851.03 (0.99–1.07)0.77
 Hematocrit (%)2,9381.01 (0.98–1.05)2,7851.03 (0.99–1.07)0.52
 Hemoglobin concentration (g/dL)2,9381.01 (0.97–1.04)2,7851.01 (0.97–1.05)0.98
 MCV (fL)2,9380.95 (0.91–0.99)2,7850.90 (0.86–0.93)0.04
 MCH (pg)2,9380.95 (0.91–0.99)2,7850.88 (0.85–0.92)0.01
 MCHC (g/dL)2,9380.99 (0.95–1.02)2,7850.94 (0.91–0.98)0.13
 MSCV (fL)2,8860.97 (0.93–1.01)2,7460.90 (0.86–0.94)0.01
 Reticulocyte count (1012 cells/L)2,8850.98 (0.94–1.03)2,7461.00 (0.96–1.04)0.57
Platelet
 Platelet count (109 cells/L)2,9381.03 (0.99–1.06)2,7851.09 (1.05–1.13)0.02
 Platelet distribution width (%)2,9380.99 (0.96–1.03)2,7850.99 (0.96–1.03)0.96
 Mean platelet volume (fL)2,8850.99 (0.96–1.03)2,7291.02 (0.98–1.05)0.42
White blood cell
 White blood cell count (109 cells/L)2,9320.99 (0.95–1.03)2,7781.04 (1.00–1.08)0.12
 Neutrophil count (109 cells/L)2,9311.01 (0.97–1.05)2,7801.05 (1.01–1.09)0.17
 Eosinophils (109 cells/L)2,9300.97 (0.93–1.01)2,7770.98 (0.94–1.02)0.87
 Basophil count (109 cells/L)2,9201.00 (0.96–1.04)2,7660.98 (0.94–1.03)0.51
 Monocyte count (109 cells/L)2,9311.00 (0.96–1.04)2,7801.00 (0.96–1.05)0.88
 Lymphocyte count (109 cells/L)2,9310.97 (0.93–1.02)2,7801.00 (0.96–1.04)0.34
  • Note: HRs per 1 SD increase are stratified by region and age at recruitment and adjusted for age (underlying time variable), Townsend deprivation score, racial/ethnic group, height, lives with a wife or partner, BMI, cigarette smoking, alcohol consumption, and diabetes. Phet was estimated using stratified Cox models based on competing risks (<4 and ≥4 years from recruitment to diagnosis), and tested using the χ2 test of heterogeneity.